Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Share-based Compensation (2016 - 2025)

Cytokinetics (CYTK) has disclosed Share-based Compensation for 15 consecutive years, with $40.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation changed N/A to $40.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $120.3 million, a N/A change, with the full-year FY2025 number at $112.3 million, up 14.76% from a year prior.
  • Share-based Compensation was $40.7 million for Q4 2025 at Cytokinetics, up from $30.7 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $40.7 million in Q4 2025 to a low of $5.3 million in Q1 2021.
  • A 5-year average of $17.4 million and a median of $16.9 million in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: soared 101.13% in 2022, then grew 8.96% in 2025.
  • Cytokinetics' Share-based Compensation stood at $6.7 million in 2021, then skyrocketed by 101.13% to $13.5 million in 2022, then skyrocketed by 44.37% to $19.5 million in 2023, then soared by 30.12% to $25.4 million in 2024, then soared by 60.5% to $40.7 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Share-based Compensation are $40.7 million (Q4 2025), $30.7 million (Q3 2025), and $23.5 million (Q1 2025).